Saturday, 8 October 2016

Melanoma abstracts

1. Christian Blank -Combi IPI/NIVO as neoadjuvant -OpACIN trial

Combi ipilimumab and nivolumab produces more side effects in neoadjuvant setting.
Small study, 20 patients
-for stage III, rezectable, with palpable limphnodes

Main goals of neoadjuvant therapies
- to reduce the microscopic disease.
- to better control the local disease

Too small to get relevant results, still promising - Recurrence Free Survival (RFS), 1 year 56%.

2. A. Ribas. Genomic features of complete responders versus fast progressors in patients with Braf mutated melanoma treated with Vemurafenib/cobimetinib versus vemurafenib alone.  

Mutational load predictor was the same in patient with complete response and the ones who were progressing- analyzing biopsies.

Interesting - Disease Progression (PD)
was related to keratinization or keratine signature

Complete responses (CR) were seen in patients with multiple gene signatures

To be continued..

No comments:

Post a Comment